Efficacy Safety and Pharmacokinetics of Rozanolixizumab in Adult Study Participants with Leucine-Rich Glioma Inactivated 1 Autoimmune Encephalitis
Brief description of study
The purpose of this study is to see if rozanolixizumab, an investigational (new) drug, is able to prevent the worsening of symptoms of Leucine-Rich Glioma Inactivated 1 Autoimmune Encephalitis (LGI1 AIE) when used in conjunction with steroids compared to treatment with steroids only.
Interested participants should reach out to CECResearchStudyInfo@nyulangone.org.
Clinical Study Identifier: s22-00047
ClinicalTrials.gov Identifier: NCT04875975
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
